Easywell Biomedicals Valuation

Is 1799 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1799 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 1799's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 1799's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1799?

Key metric: As 1799 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 1799. This is calculated by dividing 1799's market cap by their current revenue.
What is 1799's PS Ratio?
PS Ratio	22.4x
Sales	NT$361.49m
Market Cap	NT$8.10b

1799 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	22.4x
Enterprise Value/EBITDA	-70.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 1799's PS Ratio compare to its peers?

The above table shows the PS ratio for 1799 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	8.9x
6762 Delta Asia International	16.5x	n/a	NT$8.4b
4163 INTAI Technology	2.4x	n/a	NT$5.7b
4138 Dynamic Medical Technologies	2.1x	n/a	NT$3.4b
6499 Medeon Biodesign	14.5x	n/a	NT$3.9b
1799 Easywell Biomedicals	22.4x	n/a	NT$8.1b

Price-To-Sales vs Peers: 1799 is expensive based on its Price-To-Sales Ratio (22.4x) compared to the peer average (8.9x).

Price to Sales Ratio vs Industry

How does 1799's PS Ratio compare vs other companies in the TW Medical Equipment Industry?

2 Companies	Price / Sales	Estimated Growth	Market Cap
4116 BenQ Medical Technology	0.5x	n/a	US$65.41m
4121 Rossmax International	0.4x	n/a	US$44.16m

No more companies available in this PS range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 1799 is expensive based on its Price-To-Sales Ratio (22.4x) compared to the TW Medical Equipment industry average (2.8x).

Price to Sales Ratio vs Fair Ratio

What is 1799's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1799 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	22.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 1799's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Universal Vision Biotechnology

NT$17.9b

Operates a chain of eye care clinics in Taiwan and China.

3218

NT$211.00

-0.7%

-27.7%

Pacific Hospital Supply

NT$6.5b

Manufactures, processes, and sells medical disposable products and equipment in Taiwan.

4126

NT$89.00

0.7%

2.9%

Crystalvue Medical

NT$2.2b

Designs, manufactures, and sells ophthalmic medical equipment worldwide.

6527

NT$88.20

-1.3%

1.1%